Illumina (Nasdaq: ILMN ) is expected to report Q2 earnings on July 23. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Illumina's revenues will grow 18.3% and EPS will decrease 0.0%.
The average estimate for revenue is $332.0 million. On the bottom line, the average EPS estimate is $0.40.
Last quarter, Illumina booked revenue of $331.0 million. GAAP reported sales were 21% higher than the prior-year quarter's $272.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.46. GAAP EPS were -$0.18 for Q1 against $0.20 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.6%, 110 basis points better than the prior-year quarter. Operating margin was 21.1%, 60 basis points worse than the prior-year quarter. Net margin was -6.8%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $1.35 billion. The average EPS estimate is $1.68.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 671 members out of 720 rating the stock outperform, and 49 members rating it underperform. Among 202 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 193 give Illumina a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Illumina is outperform, with an average price target of $55.36.
Looking for alternatives to Illumina? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Illumina to My Watchlist.